In this issue:
Vedolizumab in primary sclerosing cholangitis and IBD
Optimal adherence threshold with subcutaneous anti-TNFs
Outcomes after infliximab withdrawal in CD
Guselkumab after inadequate response to ustekinumab
Atacicept for systemic lupus erythematosus
Belimumab for early diffuse systemic sclerosis
Tocilizumab in refractory Takayasu arteritis
Belimumab in systemic lupus erythematosus
Rituximab in primary Sjögren’s syndrome
Subcutaneous tocilizumab in systemic sclerosis
Mycophenolate mofetil for systemic sclerosis-related interstitial lung disease
Please login below to download this issue (PDF)